(VIANEWS) – Coda Octopus Group (CODA), Artisan Partners Asset Management (APAM), Medpace Holdings (MEDP) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Coda Octopus Group (CODA)
57.7% sales growth and 5.56% return on equity
Coda Octopus Group, Inc., together with its subsidiaries, develops, sells, and rentals underwater technologies and equipment for real time 3D imaging, mapping, defense, and survey applications in the United States of America and internationally. The company operates through two segments, Marine Engineering Business and Marine Technology Business. It sells technology solutions to the subsea and underwater markets. The company's solutions include geophysical systems, a geophysical data acquisition systems, processing, and analysis software that are used primarily by survey companies, offshore renewable companies, research institutions, and salvage companies; GNSS-aided navigation systems (attitude and positioning systems); Real time volumetric imaging sonar; and diver augmented vision display system. It offers CodaOctopus GeoSurvey products, such as hardware and software solutions for field acquisition of sidescan sonar and sub-bottom profiler; and CodaOctopus DA4G productivity suite of software that automates the tasks of analyzing, annotating, and mosaicing complex data sets. It markets its products under the CodaOctopus brand name. Coda Octopus Group, Inc. was founded in 1994 and is headquartered in Orlando, Florida.
Earnings Per Share
As for profitability, Coda Octopus Group has a trailing twelve months EPS of $0.24.
PE Ratio
Coda Octopus Group has a trailing twelve months price to earnings ratio of 31.21. Meaning, the purchaser of the share is investing $31.21 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.56%.
Yearly Top and Bottom Value
Coda Octopus Group’s stock is valued at $7.49 at 16:22 EST, way below its 52-week high of $8.45 and way above its 52-week low of $5.21.
Moving Average
Coda Octopus Group’s value is way above its 50-day moving average of $6.44 and way above its 200-day moving average of $6.22.
Revenue Growth
Year-on-year quarterly revenue growth grew by 0.4%, now sitting on 18.24M for the twelve trailing months.
2. Artisan Partners Asset Management (APAM)
13.1% sales growth and 55.84% return on equity
Artisan Partners Asset Management Inc. is publicly owned investment manager. It provides its services to pension and profit sharing plans, trusts, endowments, foundations, charitable organizations, government entities, private funds and non-U.S. funds, as well as mutual funds, non-U.S. funds and collective trusts. It manages separate client-focused equity and fixed income portfolios. The firm invests in the public equity and fixed income markets across the globe. It invests in growth and value stocks of companies across all market capitalization. For fixed income component of its portfolio the firm invests in non-investment grade corporate bonds and secured and unsecured loans. It employs fundamental analysis to create its portfolios. Artisan Partners Asset Management Inc. was founded in 1994 and is based in Milwaukee, Wisconsin with additional offices in Atlanta, Georgia; New York City; San Francisco, California; Leawood, Kansas; and London, United Kingdom.
Earnings Per Share
As for profitability, Artisan Partners Asset Management has a trailing twelve months EPS of $3.35.
PE Ratio
Artisan Partners Asset Management has a trailing twelve months price to earnings ratio of 11.44. Meaning, the purchaser of the share is investing $11.44 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 55.84%.
Yearly Top and Bottom Value
Artisan Partners Asset Management’s stock is valued at $38.31 at 16:22 EST, way under its 52-week high of $46.75 and way higher than its 52-week low of $32.12.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 16% and 16.7%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 11.5%, now sitting on 1.03B for the twelve trailing months.
3. Medpace Holdings (MEDP)
11.2% sales growth and 58.85% return on equity
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Earnings Per Share
As for profitability, Medpace Holdings has a trailing twelve months EPS of $10.63.
PE Ratio
Medpace Holdings has a trailing twelve months price to earnings ratio of 35.47. Meaning, the purchaser of the share is investing $35.47 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 58.85%.
4. Installed Building Products (IBP)
9.8% sales growth and 42.26% return on equity
Installed Building Products, Inc., together with its subsidiaries, engages in the installation of insulation, waterproofing, fire-stopping, fireproofing, garage doors, rain gutters, window blinds, shower doors, closet shelving and mirrors, and other products in the continental United States. The company offers a range of insulation materials, such as fiberglass and cellulose, and spray foam insulation materials. It is also involved in the installation of insulation and sealant materials in various areas of a structure, which includes basement and crawl space, building envelope, attic, and acoustical applications. In addition, the company installs a range of caulk and sealant products that control air infiltration in residential and commercial buildings; and waterproofing options, including sheet and hot applied waterproofing membranes, as well as deck coating, bentonite, and air and vapor systems. It serves homebuilders, multi-family and commercial construction firms, individual homeowners, and repair and remodeling contractors through a network of approximately 210 branch locations. The company was formerly known as CCIB Holdco, Inc. Installed Building Products, Inc. was founded in 1977 and is based in Columbus, Ohio.
Earnings Per Share
As for profitability, Installed Building Products has a trailing twelve months EPS of $8.85.
PE Ratio
Installed Building Products has a trailing twelve months price to earnings ratio of 27.18. Meaning, the purchaser of the share is investing $27.18 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 42.26%.
Sales Growth
Installed Building Products’s sales growth is 7.7% for the present quarter and 9.8% for the next.
Moving Average
Installed Building Products’s value is way above its 50-day moving average of $213.70 and way higher than its 200-day moving average of $198.87.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 9.9% and 11.1%, respectively.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jun 14, 2024, the estimated forward annual dividend rate is 1.4 and the estimated forward annual dividend yield is 0.58%.
5. PulteGroup (PHM)
9.3% sales growth and 27.3% return on equity
PulteGroup, Inc., through its subsidiaries, primarily engages in the homebuilding business in the United States. It acquires and develops land primarily for residential purposes; and constructs housing on such land. The company also offers various home designs, including single-family detached, townhomes, condominiums, and duplexes under the Centex, Pulte Homes, Del Webb, DiVosta Homes, American West, and John Wieland Homes and Neighborhoods brand names. As of December 31, 2022, it controlled 211,112 lots, of which 108,848 were owned and 102,264 were under land option agreements. In addition, the company arranges financing through the origination of mortgage loans primarily for homebuyers; sells the servicing rights for the originated loans; and provides title insurance policies, and examination and closing services to homebuyers. The company was founded in 1950 and is headquartered in Atlanta, Georgia.
Earnings Per Share
As for profitability, PulteGroup has a trailing twelve months EPS of $12.48.
PE Ratio
PulteGroup has a trailing twelve months price to earnings ratio of 10.07. Meaning, the purchaser of the share is investing $10.07 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 27.3%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 1.9% and 10.3%, respectively.
6. Grifols, S.A. (GRFS)
8.3% sales growth and 3.48% return on equity
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum–from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring–to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
Earnings Per Share
As for profitability, Grifols, S.A. has a trailing twelve months EPS of $0.1.
PE Ratio
Grifols, S.A. has a trailing twelve months price to earnings ratio of 77.4. Meaning, the purchaser of the share is investing $77.4 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.48%.
Yearly Top and Bottom Value
Grifols, S.A.’s stock is valued at $7.74 at 16:22 EST, way under its 52-week high of $12.15 and way above its 52-week low of $5.30.
Sales Growth
Grifols, S.A.’s sales growth is 7.8% for the current quarter and 8.3% for the next.
Moving Average
Grifols, S.A.’s worth is higher than its 50-day moving average of $7.42 and under its 200-day moving average of $7.99.
Revenue Growth
Year-on-year quarterly revenue growth grew by 4.1%, now sitting on 6.66B for the twelve trailing months.
